Candel Therapeutics, Inc. (CADL) Ownership
CADL ownership summary
as of October 18, 2026- Institutions
- 67.7% of shares outstanding
- Insiders
- 14.65% of shares outstanding
- Shares outstanding
- 76.5M
- Float
- 60.2M shares available to trade
- Short interest
- 21.85% 13.0M shares short
- Days to cover
- 11.02 short interest up 5.3% vs prior month
- Institutions 67.67%
- Insiders 14.65%
- Other investors 17.68%
CADL top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | FMR Inc | 14.36% | 11.0M | $90.0M | +3,518 (+0.0%) | June 30, 2026 |
| 2 | RTW INVESTMENTS, LLC | 8.39% | 6.4M | $52.6M | — | June 30, 2026 |
| 3 | BlackRock Inc | 6.49% | 5.0M | $40.7M | +1.9M (+59.8%) | June 30, 2026 |
| 4 | State Street Corp | 4.64% | 3.5M | $29.1M | +2.7M (+333.7%) | June 30, 2026 |
| 5 | Portolan Capital Management, LLC | 4.56% | 3.5M | $28.6M | +596,073 (+20.6%) | June 30, 2026 |
| 6 | Saturn V Capital Management LLC | 4.32% | 3.3M | $27.1M | +407,098 (+14.1%) | June 30, 2026 |
| 7 | Vanguard Capital Management, LLC | 3.52% | 2.7M | $22.1M | +231,283 (+9.4%) | June 30, 2026 |
| 8 | Geode Capital Management, LLC | 2.05% | 1.6M | $12.9M | +535,586 (+51.7%) | June 30, 2026 |
| 9 | Millennium Management LLC | 1.43% | 1.1M | $9.0M | +33,819 (+3.2%) | June 30, 2026 |
| 10 | Halter Ferguson Financial Inc | 1.01% | 772K | $6.3M | −131,590 (−14.6%) | June 30, 2026 |
| 11 | Northern Trust Corp | 0.64% | 492K | $4.0M | +169,311 (+52.4%) | June 30, 2026 |
| 12 | Kennedy Capital Management Inc | 0.64% | 488K | $4.0M | +395,666 (+427.2%) | June 30, 2026 |
| 13 | Vanguard Portfolio Management, LLC | 0.57% | 437K | $3.6M | +168,901 (+63.0%) | June 30, 2026 |
| 14 | Vanguard Fiduciary Trust Co | 0.54% | 412K | $3.4M | +131,658 (+46.9%) | June 30, 2026 |
| 15 | Sands Capital Ventures, LLC | 0.53% | 406K | $3.3M | — | June 30, 2026 |
| 16 | The Goldman Sachs Group Inc | 0.40% | 305K | $2.5M | +77,695 (+34.1%) | June 30, 2026 |
| 17 | Marshall Wace Asset Management Ltd | 0.39% | 301K | $2.5M | +300,641 (0.0%) | June 30, 2026 |
| 18 | Arete Wealth Advisors, LLC | 0.38% | 290K | $2.4M | +289,663 (0.0%) | June 30, 2026 |
| 19 | Bank of America Corp | 0.36% | 279K | $2.3M | +231,542 (+488.5%) | June 30, 2026 |
| 20 | Susquehanna International Group, LLP | 0.30% | 228K | $1.9M | +114,966 (+101.8%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 17 holders added 8.3M shares and 1 cut 132K.
CADL top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Fidelity Select Biotechnology | 6.36% | 4.9M | $39.8M | — | August 31, 2026 |
| 2 | Fidelity Growth Company Fund | 2.99% | 2.3M | $18.8M | +182,783 (+8.7%) | August 31, 2026 |
| 3 | State Street® SPDR® S&P® Biotech ETF | 2.87% | 2.2M | $18.0M | −41,900 (−1.9%) | September 30, 2026 |
| 4 | Vanguard MStar Total Stk Mkt Idx Invest | 2.57% | 2.0M | $16.1M | — | August 31, 2026 |
| 5 | Strategic Advisers U.S. Total Stock | 2.50% | 1.9M | $15.7M | — | August 31, 2026 |
| 6 | iShares Russell 2000 ETF | 2.17% | 1.7M | $13.6M | −19,136 (−1.1%) | September 30, 2026 |
| 7 | Fidelity Small Cap Index | 0.91% | 693K | $5.7M | +5,423 (+0.8%) | July 31, 2026 |
| 8 | Fidelity Growth Company K6 | 0.86% | 659K | $5.4M | +54,483 (+9.0%) | August 31, 2026 |
| 9 | Fidelity Series Growth Company | 0.79% | 603K | $4.9M | +47,009 (+8.5%) | August 31, 2026 |
| 10 | iShares Russell 2000 Growth ETF | 0.72% | 548K | $4.5M | −694 (−0.1%) | September 30, 2026 |
| 11 | iShares Biotechnology ETF | 0.62% | 472K | $3.9M | −3,576 (−0.8%) | September 30, 2026 |
| 12 | Schwab US Small-Cap ETF™ | 0.49% | 376K | $3.1M | +252 (+0.1%) | September 30, 2026 |
| 13 | MEDICAL BioHealth EUR Acc | 0.48% | 371K | $3.0M | −92,228 (−19.9%) | August 31, 2026 |
| 14 | Vanguard Russell 2000 ETF | 0.48% | 365K | $3.0M | +8,916 (+2.5%) | August 31, 2026 |
| 15 | Fidelity Extended Market Index | 0.36% | 279K | $2.3M | −3,554 (−1.3%) | August 31, 2026 |
| 16 | BANOR SICAV Rosemary S EUR Acc | 0.36% | 272K | $2.2M | −137,900 (−33.6%) | June 30, 2026 |
| 17 | Stt Strt®SPDR®S&PKenshoNwEcosComposETF | 0.34% | 263K | $2.2M | — | September 30, 2026 |
| 18 | iShares Micro-Cap ETF | 0.26% | 200K | $1.6M | −1,378 (−0.7%) | September 30, 2026 |
| 19 | Schwab Small Cap Index | 0.20% | 154K | $1.3M | — | August 31, 2026 |
| 20 | Stt Strt SPDR® Russell2000 US SmCapETF | 0.17% | 128K | $1.0M | +6,112 (+5.0%) | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
CADL insider transactions
latest 3| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-23 | Paul B Manning | Buy | $5.45 | 550,458 | $3.0M |
| 2025-07-28 | William Garrett Nichols | Sell | $6.98 | 937 | $6,540 |
| 2025-06-30 | William Garrett Nichols | Sell | $5.04 | 781 | $3,936 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
CADL shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns CADL
Institutional investors own 67.7% of Candel Therapeutics's shares and insiders 14.65%. The largest holder is FMR Inc with 14.36% of the shares (11.0M), as of June 30, 2026. Among the top 20 institutions, 17 added shares and 1 reduced their stake in the latest filings. Short interest is 21.85% of the float, or 11.02 days of average trading volume. The share count rose 372.6% since 2020.
Related: CADL analyst forecast, CADL key metrics. See the CADL stock overview for the latest quote and news.
CADL ownership FAQ
Who owns the most Candel Therapeutics stock?
The largest shareholders of Candel Therapeutics are FMR Inc (14.36%), RTW INVESTMENTS, LLC (8.39%), BlackRock Inc (6.49%), State Street Corp (4.64%), Portolan Capital Management, LLC (4.56%).
What percentage of Candel Therapeutics is owned by institutions?
Institutions hold 67.7% of Candel Therapeutics's shares outstanding; insiders hold 14.65%.
Which funds own Candel Therapeutics?
The largest fund holders of Candel Therapeutics are Fidelity Select Biotechnology (6.36%), Fidelity Growth Company Fund (2.99%), State Street® SPDR® S&P® Biotech ETF (2.87%), Vanguard MStar Total Stk Mkt Idx Invest (2.57%), Strategic Advisers U.S. Total Stock (2.50%).
What is Candel Therapeutics's short interest?
13.0M shares of Candel Therapeutics were sold short, 21.85% of the float; at the average daily volume it would take 11.02 days to cover.
Are insiders buying or selling Candel Therapeutics?
Of the latest 3 reported insider transactions in Candel Therapeutics (since June 30, 2025), 1 were purchases and 2 were sales.
How many shares of Candel Therapeutics are outstanding?
Candel Therapeutics has 76.5M shares outstanding, of which 60.2M are in the public float.